Author:
Stein Eytan,Xie Jipan,Duchesneau Emilie,Bhattacharyya Subrata,Vudumula Umakanth,Ndife Briana,Bonifacio Gaetano,Guerin Annie,Li Nanxin,Joseph George
Funder
Novartis Pharmaceuticals Corporation
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference36 articles.
1. De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6:e441.
2. American Cancer Society. What are the key statistics about acute myeloid leukemia? Available at:
https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html
. Accessed 22 Sep 2018.
3. National Cancer Institute. Cancer stat facts: acute myeloid leukemia (AML). 2017. Available at:
https://seer.cancer.gov/statfacts/html/amyl.html
. Accessed Sep 2017.
4. Sotak M, Marin M, Coombs J, Teitelbaum A, editors. The burden of illness (BOI) of FLT3-mutated acute myeloid leukemia in the United States. In: 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting; Washington, DC.
5. Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23(9):1969–78.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献